
New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

Chun spoke in this interview segment about more recommendations for internal medicine physicians to give older adults related to aging, dementia, and statin use.

The fracture risk is greater for nursing home residents with dementia, greater baseline blood pressure values, and no recent antihypertensive medication use, a new study found.

Solomon discusses the health care system’s role in mitigating climate change and how health care professionals can help protect and inform their patients.

Article intelligence chatbots, including ChatGPT and Bard, varied in accuracy, comprehensiveness, and readability on glaucoma questions adapted from patient brochures.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

In this interview, Chun discussed recommendations for internal medicine physicians to give older adults for slowing aging as well as evidence for statins.

Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.

In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.


Solomon explains how the health care system contributes to climate change and the direct health impacts seen as a result, based on her session at ACP.

This segment of Hemming’s ACP interview featured a discussion of a website used to assess digital applications for patients struggling with mental health issues.

The first in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on basic considerations surrounding Lp(a) measurement.

A new study found female patients (8.15%) had a lower mortality rate when treated by female physicians than male physicians (8.38%).

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Rilzabrutinib led to a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia in the LUNA 3 study.

Branch provides an overview of the use of dual antiplatelet therapy and anticoagulants based on his session at the ACP Internal Medicine meeting.

Another segment of her ACP 2024 interview featured a discussion on weight loss drugs, healthy living, and discussions with patients.

NBI-1065845 shows promise in alleviating symptoms of major depressive disorder in patients with inadequate response to current antidepressant treatments, according to phase 2 SAVITRI study data.

A new study found the perceived onset of old age rose nearly 3 years from 1911 to 1953.

Shah discusses the prevalence of psychiatric illness among hospitalized patients and highlights key considerations for their management from her session at ACP.

The national registry-based analysis in Denmark may inform the clinical value of medication adherence in the first years of glaucoma treatment.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.

Cerceo, Peden, and Ziska joined HCPLive to speak on the imminent threat posed by climate change, highlighting the impact especially on individuals with allergic disease.

Nahas reviews key highlights from her session at ACP, emphasizing the importance of reviewing patient history and considering what other factors may be causing headaches.